ClinicalTrials.gg
Not yet recruitingNCT07648407Updated Oct 6, 2026

Therapeutic Induction of Dermal Remodeling in Veterans to Prevent Actinic Neoplasia Caused by Chronic Environmental Exposure to Ultraviolet Radiation

An interventional study of Microneedling and Trichloroacetic acid peel in Nonmelanoma Skin Cancer and Actinic Keratosis, sponsored by VA Office of Research and Development. Not yet recruiting at 2 sites in United States. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by VA Office of Research and Development · Not applicable, Interventional, and Prevention

How we know

Updated Oct 6, 2026Start date movedEligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 165 studies in Keratosis, Actinic with a site in United States — 16 open to participants now, 21 under way, 4 of them phase 3. Keratosis, Actinic · United States.

Planned enrollment
66th of 152
96 · median 73
Started
2026
with 10 others
No phase
22 of 165
4 open now
Primary completion
2030-09
later than 18 of 20 live
Registered
162nd of 165
by date

Among the 165 studies in Keratosis, Actinic with a site in United States, this one is the 66th largest by planned enrollment of the 152 interventional ones that give a count, is one of 11 that started in 2026, is one of 22 with no phase, reaches primary completion later than 18 of the 20 other live ones, and was the 162nd registered.

Keratosis, Actinic

343 studies on the registry are indexed under Keratosis, Actinic; 30 are open to participants now.

Browse Keratosis, Actinic studies →

Open to participants now

16 of the 165 studies in Keratosis, Actinic with a site in United States are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 22 Keratosis, Actinic studies recruiting now, 17 (77%) set no upper age limit and 1 (5%) stops at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 165 studies in Keratosis, Actinic with a site in United States, or all of them as a file.
02

Study summary

The investigators' previous studies demonstrate geriatric subject skin responds differently to ultraviolet B (UVB) light compared to young subject skin, which contribute to increased rates of nonmelanoma skin cancer (NMSC) and actinic keratosis (AK) development in geriatric populations. Previously, the investigators have shown that therapeutic dermal remodeling interventions (e.g., fractionated laser resurfacing and microneedling) can restore appropriate skin responses to UVB in geriatric skin. The investigators also demonstrated fractionated laser resurfacing (FLR) reduced rates of NMSC and AK development (compared to untreated control skin) in at risk geriatric subjects.

This interventional study will assess the ability of two therapeutic dermal remodeling therapies, microneedling and trichloroacetic acid chemical (TCA) peel, to impact NMSC and AK development in at risk geriatric subjects. Geriatric subjects will be enrolled into one of two study groups. In the first group, one arm will be treated with microneedling and the other arm will not be treated on day 1. In the second group, one arm will be treated with TCA peel and the other arm will not be treated on day 1. Subjects will subsequently be monitored for number of NMSC and AK on treated and untreated (control) forearms in each group. In addition to monitoring NMSC and AK development, subjects at the Richard L. Roudebush VAMC will undergo skin punch biopsy at one of their follow up visits for microscopic and molecular analyses of treated and untreated skin.

03

Conditions studied

  • Nonmelanoma Skin Cancer
  • Actinic Keratosis

Browse trials for

Keywords

  • Nonmelanoma skin cancer
  • Actinic keratosis
  • Ultraviolet light
  • Microneedling
  • Chemical peel
04

Who can participate

The criteria were revised on the registry on Oct 6, 2026. See what changed

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 5 or more actinic keratosis (AKs) on each forearm
  • Skin type fair-Fitzpatrick I-II
  • Able to comprehend procedures and risks

Exclusion criteria

Exclusion Criteria:

  • More than 10 actinic keratosis (AKs) on an extremity, or AKs that are large (2-3+)
  • Medical history of diabetes
  • Coagulopathy or easy bleeding
  • History of poor wound healing or scarring
  • Large tattoos that can interfere with study
  • Other serious health issues and other skin diseases that could interfere with the study
  • Recent (within 1 year) field therapies such as Efudex cream or photodynamic therapy (PDT) to forearms
  • Planning to leave region in next 4 years
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
96 participants (estimated)

Study arms

  • Experimental
    Microneedling - Male

    Forearm treatment with microneedling

    Other: Microneedling

  • Experimental
    Microneedling - Female

    Forearm treatment with microneedling

    Other: Microneedling

  • Experimental
    Trichloroacetic acid peel - Male

    Forearm treatment with trichloroacetic acid peel

    Other: Trichloroacetic acid peel

  • Experimental
    Trichloroacetic acid peel - Female

    Forearm treatment with trichloroacetic acid peel

    Other: Trichloroacetic acid peel

Interventions

  • OtherMicroneedling

    Microneedling- a mechanical tool that makes tiny holes in a superficial part of the skin

  • OtherTrichloroacetic acid peel

    Trichloroacetic acid peel that removes a superficial part of the skin

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Number of Actinic Keratosis due to treatment.

    Investigator will assess the number of actinic keratosis on both forearms

    Time frame: up to 4 years

  2. Change From Baseline in the Number Non-Melanoma Skin Cancers due to treatment.

    Investigator will assess the number of nonmelanoma skin cancers on both forearms.

    Time frame: up to 4 years

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Sep 2030, 46 months later.

Of 33 interventional studies with no phase under Keratosis, Actinic, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 33. This study's planned 46 months is above that.

Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Nov 2026, on Oct 6, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2026
First posted
Jun 15, 2026
StartEst.
Nov 1, 2026was Oct 2026
Primary completionEst.
Sep 30, 2030
CompletionEst.
Sep 30, 2030
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Oct 1, 2026→Nov 1, 2026
Oct 6, 2026
Eligibility
1 inclusion criterion edited; 2 exclusion criteria edited
What changed in the criteria
Inclusion criteria
  • EditedAdult Males and Females age 60 and older with 5 or more actinic keratosis (AKs) on each forearm
Exclusion criteria
  • EditedMore than 10 actinic keratosis (AKs) on an extremity, or AKs that are large (2-3+)
  • EditedRecent (within 1 year) field therapies such as Efudex cream or photodynamic therapy (PDT) to forearms
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Start date Oct 1, 2026→Nov 1, 2026
    Eligibility 1 inclusion criterion edited; 2 exclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • EditedAdult Males and Females age 60 and older with 5 or more actinic keratosis (AKs) on each forearm
    Exclusion criteria
    • EditedMore than 10 actinic keratosis (AKs) on an extremity, or AKs that are large (2-3+)
    • EditedRecent (within 1 year) field therapies such as Efudex cream or photodynamic therapy (PDT) to forearms
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07648407
Responsible party
Sponsor
First posted
Jun 15, 2026
Start date
Nov 1, 2026 (estimated)
Primary completion
Sep 30, 2030 (estimated)
Completion
Sep 30, 2030 (estimated)
Last update
Oct 6, 2026

Study contacts

Matthew J Turner, MD
Contact
matthew.turner@va.gov
(317) 988-5000
Matthew J Turner, MD
principal investigator · Richard L. Roudebush VA Medical Center, Indianapolis, IN

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion